Karuna Therapeutics, Inc. (KRTX) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Boston, MA, United States. वर्तमान CEO हैं William Meury.
KRTX के पास है IPO तिथि 2019-06-28, 339 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Market, बाजार पूंजीकरण $12.6B.
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines for psychiatric and neurological disorders. The company's lead product candidate, KarXT, is an oral muscarinic receptor modulator currently in Phase III clinical trials for treating acute psychosis in schizophrenia patients, as well as negative and cognitive symptoms associated with schizophrenia, psychosis, and dementia-related psychosis. Karuna has established strategic partnerships with major pharmaceutical and research organizations, including Eli Lilly and Company, Zai Lab, PureTech Health, Charles River Laboratories, and PsychoGenics, Inc. Based in Boston, Massachusetts, the company was incorporated in 2009 and rebranded as Karuna Therapeutics in 2019 to reflect its expanded therapeutic focus.
